No Data
Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
7 Analysts Assess Alkermes: What You Need To Know
Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview of recent rat
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
Alkermes Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 45.77% HC Wainwright & Co. → $35 Reiterates Neutral → Neutral 04/19/2024 45.77% HC Wainwright &
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline